Strides Strengthens its Africa Business with Acquisition of Generic Brands from Sandoz
Bangalore, India, March 17, 2026 – Strides Pharma Science Limited (Strides) announced that its step-down subsidiary, Strides Pharma International AG (SPIAG), has entered into definitive agreements with Sandoz AG and its group entities for the acquisition and in-licensing of a portfolio of branded generic products across Sub-Saharan Africa (SSA).The agreement spans four key markets: Western Sahara, Ghana, Nigeria, and Kenya, encompassing brands across anti-infective, cardiovascular, and dermatology therapeutic segments. Several products individually deliver annual sales exceeding US$1 million.
The transaction includes both fully acquired products and select products that Strides will market on behalf of Sandoz. A Manufacturing and Supply Agreement with Sandoz will ensure uninterrupted product availability.
With this acquisition, Strides is expected to become one of the top five pharmaceutical companies in the SSA region by sales and among the top two players in the represented market.
The initial consideration for the transaction is US$12 million, payable at closing and expected to be funded through internal accruals. The transaction is projected to be EPS-accretive and is expected to close by the end of Q2 FY27 (Quarter Ending September 30, 2026), subject to customary closing conditions, including regulatory and antitrust approvals.
According to Aditya Kumar, Executive Director, Business Development, this acquisition strengthens Strides’ “in Africa for Africa” strategy and more than doubles the company's presence in the region.
About Strides
Strides, a global pharmaceutical company headquartered in Bengaluru, India, is listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR). The company operates in regulated markets and has an "in Africa for Africa" strategy, alongside an institutional business to service donor-funded markets. Strides' global manufacturing sites are located in India, Italy, Kenya, and the United States.
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.